VivoSeq
Respiratory

Lymphangioleiomyomatosis

14

Pipeline Programs↗

3

Active Trials↗

6

Companies Involved↗

Lymphangioleiomyomatosis is an emerging landscape with 14 programs across 6 companies. The most active players are Boehringer Ingelheim, Sun Pharma, Prism Pharmaceuticals. 3 therapies are approved with 2 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

42/100

Pipeline Velocity

6/100

Mech. Concentration

20/100

Completion Rate

91/100

Attrition Rate

7/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Boehringer Ingelheim logo

Boehringer Ingelheim

1 program

Phase 2Sun Pharma logo

Sun Pharma

1 program

Phase 2P

Prism Pharmaceuticals

1 program

Phase 3Novartis logo

Novartis

2 programs

Phase 3G

Glaxo Dba Glaxosmithkline

1 program

ApprovedP

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

1 program

Approved

Pipeline

Programs by Phase

Analysis

Modality Breakdown

93%

Small molecule

14 of 15 classified programs — the dominant modality here.

7%ALL OTHERSPeptide17%

Small molecule leads; the ring shows all 15 classified programs, each share of the total. Modality classified for 100% of 15 pipeline programs.

Analysis

Trial Status

15

clinical trials

Completed10 · 67%
Recruiting2 · 13%
Active, not recruiting1 · 7%
Terminated1 · 7%
Unknown status1 · 7%

Clinical Trials

Trial Activity

15 trials

Evaluating the Long-term Safety and Tolerability of Imatinib in Patients With Lymphangioleiomyomatosis (LAM)
Recruiting·—·Phase 1·NCT06889168·20 enrolled
Nebulized or Inhaled Albuterol for Lymphangioleiomyomatosis
Recruiting·National Heart, Lung, and Blood Institute (NHLBI)·Phase 1/2·NCT01799538·100 enrolled
Multicenter Interventional Lymphangioleiomyomatosis (LAM) Early Disease Trial
Active, not recruiting·UUniversity of Cincinnati·Phase 3·NCT03150914·60 enrolled
Doxycycline In Lymphangioleiomyomatosis (LAM)
Completed·UUniversity of Nottingham·Phase 4·NCT00989742·24 enrolled
A Study to Determine the Safety and Effectiveness of RAD001 (Everolimus) in Patients With Lymphangioleiomyomatosis
Completed·Novartis logoNovartis·Phase 2·NCT01059318·24 enrolled
The Tolerability of Saracatinib in Subjects With Lymphangioleiomyomatosis (LAM) (SLAM-1)
Completed·—·Phase 1·NCT02116712·9 enrolled
A Study of Nintedanib for LymphAngioleioMyomatosis (LAM)
Completed·IIRCCS Multimedica·Phase 2·NCT03062943·30 enrolled
Resveratrol and Sirolimus in Lymphangioleiomyomatosis Trial
Completed·UUniversity of Cincinnati·Phase 2·NCT03253913·25 enrolled
Safety Study of Sirolimus and Hydroxychloroquine in Women With Lymphangioleiomyomatosis
Completed·—·Phase 1·NCT01687179·14 enrolled
Efficacy and Safety of RAD001 in Patients Aged 18 and Over With Angiomyolipoma Associated With Either Tuberous Sclerosis Complex (TSC) or Sporadic Lymphangioleiomyomatosis (LAM)
Completed·Novartis logoNovartis·Phase 3·NCT00790400·118 enrolled
Letrozole for Lymphangioleiomyomatosis
Completed·UUniversity of Cincinnati·Phase 2·NCT01353209·17 enrolled
Treatment With Octreotide in Patients With Lymphangioleiomyomatosis
Completed·National Heart, Lung, and Blood Institute (NHLBI)·Phase 2·NCT00005906·4 enrolled
Long Term Follow Up for RAD001 Therapy of Angiomyolipomata in Patients With Tuberous Sclerosis (TSC) and Sporadic Lymphangioleiomyomatosis (LAM)
Completed·—·Phase 1/2·NCT00792766·20 enrolled
Safety and Efficacy of Saracatinib In Subjects With Lymphangioleiomyomatosis
Terminated·—·Phase 2·NCT02737202·28 enrolled
Effect of Loratadine in Lymphangioleiomyomatosis
Unknown status·IInstitut d'Investigació Biomèdica de Bellvitge·Phase 2·NCT05190627·62 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)